OncoSec Medical Inc Buchwert je Aktie
Was ist das Buchwert je Aktie von OncoSec Medical Inc?
Buchwert je Aktie von OncoSec Medical Inc ist 0.00
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu OncoSec Medical Inc
Was macht OncoSec Medical Inc?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
Unternehmen mit buchwert je aktie ähnlich OncoSec Medical Inc
- Cycliq hat Buchwert je Aktie von 0.00
- B. Riley Principal Merger II hat Buchwert je Aktie von 0.00
- FG Acquisition hat Buchwert je Aktie von 0.00
- Nexway AG hat Buchwert je Aktie von 0.00
- THC Therapeutics hat Buchwert je Aktie von 0.00
- Thoma Bravo Advantage hat Buchwert je Aktie von 0.00
- OncoSec Medical Inc hat Buchwert je Aktie von 0.00
- Canada Rare Earth hat Buchwert je Aktie von 0.00
- Galilee hat Buchwert je Aktie von 0.00
- PT Aneka Tambang Tbk hat Buchwert je Aktie von 0.00
- Coho Collective Kitchens hat Buchwert je Aktie von 0.00
- My Rewards International Ltd hat Buchwert je Aktie von 0.00
- Six Sigma Metals hat Buchwert je Aktie von 0.00